IDEAYA Biosciences, Inc. filed an 8-K on November 4, 2026, announcing its scheduled participation in three investor relations events in London during November 2026, including a company-hosted R&D Day featuring clinical and preclinical pipeline data.

Key Highlights

  • Three events in London: IDEAYA disclosed participation in the UBS Global Biopharma Conference, an Investor R&D Day, and the Jefferies Global Healthcare Conference, all on November 16-17, 2026.
  • R&D Day content: The Investor R&D Day, scheduled for November 16, 2026 at 5:00 PM GMT, is set to include Phase 1 dose escalation clinical data for IDE892, described in the filing as a potential best-in-class MTA-cooperative PRMT5 inhibitor.
  • Pipeline focus: The filing identifies IDE892 (PRMT5, Phase 1), a CDKN2A program targeting an IND submission in H1 2027, and IDE574 (KAT6/7, Phase 1) as programs to be addressed at the R&D Day.
  • Key speakers named: CEO Yujiro S. Hata will participate in the UBS and Jefferies fireside chats; President of Research and Development Michael White and CFO Joshua Bleharski will also join the Jefferies chat.
  • Webcast availability: According to the filing, live audio webcasts will be available on IDEAYA's investor relations website, with replays accessible for 30 days following each live event.
  • Guest presenter: Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center is noted as a featured participant at the R&D Day.

IDEAYA Biosciences Outlines November London Conference Schedule and R&D Day Program

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company focused on the discovery and development of targeted therapeutics for cancer, announced via an 8-K filed November 4, 2026, its participation in a series of investor-facing events to be held in London. The company disclosed three distinct engagements spanning November 16 and 17, 2026, each addressing different aspects of IDEAYA's pipeline and corporate strategy.

The company's own Investor R&D Day, scheduled for Monday, November 16, 2026 at 5:00 PM GMT (12:00 PM EST), is described in the filing as the most substantive event. It is set to feature a pharmacokinetics, safety, and human plasma SDMA pharmacodynamics data summary from the Phase 1 dose escalation study of IDE892, alongside preclinical data supporting IDEAYA's combination strategies in MTAP/CDKN2A and RAS-driven indications including PDAC, NSCLC, and CRC. The filing also states that the event will address the company's RAS program and anticipated 2027 clinical data updates and milestones in MTAP/CDKN2A and KRAS. Advance registration is required for both in-person and virtual attendance, according to the filing.

The UBS Global Biopharma Conference fireside chat is scheduled for 10:40 AM GMT on November 16, 2026, and will feature CEO Yujiro S. Hata in a discussion hosted by Michael Yee, Global Head of Biotechnology Research and Managing Director, Senior Biotechnology and Pharma Analyst at UBS. The Jefferies Global Healthcare Conference session follows on November 17, 2026 at 1:00 PM GMT, with Hata joined by Michael White, President of Research and Development, and CFO Joshua Bleharski. The filing notes the Jefferies discussion will be hosted by Maury Raycroft, Ph.D., Equity Research Analyst, Biotechnology. The filing contains forward-looking statements, which IDEAYA attributed to the Private Securities Litigation Reform Act of 1995 and noted are subject to risks including uncertainties inherent in preclinical and clinical development and the possibility that early results may not predict future outcomes.

What Was Disclosed

IDEAYA Biosciences disclosed its participation in three investor events in London on November 16-17, 2026, including a company-hosted R&D Day covering Phase 1 IDE892 data, RAS and CDKN2A pipeline updates, and 2027 development milestones, along with fireside chats at UBS and Jefferies conferences.